stockrow
Saturday 7 November 2026
Export PMN’s income statement to Excel — free account
Promis Neurosciences
- EPS
- +82.3%
- Free cash flow
- −169.5%
Quarter to June 2026, against a year earlier
4.07
0.42
+11.51%
Follow PMN
Alert me
Promis Neurosciences (PMN) EV/Sales
As of 6 November 2026, Promis Neurosciences (PMN) trades at a EV/Sales of −5,573×. Over the past ten years it has ranged from −10,020× (November 2026) to 121,985× (October 2019); the current reading is higher than 0% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 10,419× | (65.60%) |
| FY2019 | 30,293× | 402.69% |
| FY2018 | 6,026× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2020 | 10,419× | (52.93%) |
| Jun 2020 | 22,138× | (26.92%) |
| Dec 2019 | 30,293× | (73.97%) |
| Sep 2019 | 116,359× | 2.59% |
| 7 more quarters | Free account |
Against its own ten years
Low −10,020×
High 121,985×
Ten-year median
11,117×
Current reading's percentile
0
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PMN Promis Neurosciences | −5,573× |
| EYPT EyePoint, Inc. compare | −41.1× |
| IRLA IRulya Therapeutics Inc. compare | n/m |
| GRDX GridAI Technologies Corp. compare | n/m |
| NNVC NanoViricides, Inc. compare | n/m |
| LIANY LianBio Sponsored ADR compare | n/m |
| VERU Veru Inc. compare | 1.4× |
| PTHS Pelthos Therapeutics Inc. compare | 1.9× |
| INMB INmune Bio, Inc. compare | 121× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)